Navigation Links
DUSA Pharmaceuticals to Present at the 4th Annual Maxim Group Growth Conference
Date:11/11/2010

WILMINGTON, Mass., Nov. 11, 2010 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the 4th Annual Maxim Group Growth Conference on Thursday, November 18, 2010 at 8:30 a.m. ET at The Grand Hyatt Hotel in New York City.  Interested parties can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website for 90 days following the presentation.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform, and other dermatology products.  Levulan® Kerastick® for topical solution plus DUSA's BLU-U® blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.  DUSA also markets other dermatology products, including ClindaReach®.  DUSA is based in Wilmington, Mass.  Please visit our website at www.dusapharma.com.


'/>"/>
SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... -- Women everywhere know how frustrating a vaginal infection ... often also embarrassing and have a way of derailing ... http://ph-defense.com ) is a new, over-the-counter product designed to ... Odor, discharge, and discomfort or itch ... many cases, the cause of such problems can be ...
(Date:9/17/2014)... , Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... of its public offering of 4,500,000 shares of its common ... $9.25 per share. Aratana has granted the underwriters ... additional 675,000 shares of its common stock. ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today ... midazolam injection, USP, a general anesthetic.  Sagent expects ... latex-free vials, in 2011.  According to 2010 IMS ... approximated $52 million.   "Approval of ...
... Genous Stent shows favorable outcomes compared to bare metal stents ... to data published online in the journal Atherosclerosis ... primary endpoint, the composite of cardiac death, myocardial infarction (MI) ... 12.4% in patients treated with a Genous Stent, a 30% ...
Cached Medicine Technology:Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP 2OrbusNeich's Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents 2
(Date:9/17/2014)... People who struggle to distinguish between a business ... and get the answer by reading Per Wickstrom’s latest ... that a business plan and a business strategy are both ... Wickstrom. “The way I view it is that a business ... is part two.” , According to the blog post, ...
(Date:9/17/2014)... IL (PRWEB) September 17, 2014 The ... Pseudomonas aeruginosa infections allegedly caused by Non-Sterile Other-Sonic ... learn more about their options for legal recourse. Other-Sonic ... Drug Administration (FDA) in March 2012, after the product ... aeruginosa at William Beaumont Hospital in Royal Oak, Michigan ...
(Date:9/17/2014)... Dennis Thompson HealthDay ... -- Exposure in the womb to household chemicals known ... developing asthma, Columbia University researchers reported in a new ... risk of developing asthma between age 5 and 11 ... levels of two phthalates (pronounced thal-ates), the researchers found. ...
(Date:9/17/2014)... Texas (PRWEB) September 17, 2014 Prevention ... outbreak that is hospitalizing scores of infants, children and ... says Dr. Kirk Mahon, medical director of Legacy ER ... “There have been no reported cases of EV-D68 so ... and Louisiana, that could change,” he said. “Implementing prevention ...
(Date:9/17/2014)... 2014 Smart Flour Foods™ has been ... Grocer, a leading trade magazine targeted toward food retailers. ... and flavor, among other attributes. Smart Flour Foods’ Uncured ... in the September print issue of Progressive Grocer as ... pizza won based on its superior performance in the ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2
... for the purpose of drug testing which is currently ... at the University of Manchester, well supported with a ... carcinogenic effects of new drugs are often fruitless using ... animals to establish their safety. ,Gentronix , a ...
... are the latest to join the fight against HIV with ... clients.// They have been recruited as part of an innovative ... the British government. This donation is expected to aid in ... by increasing testing and encouraging safer sex. ...
... gain at bay, says a Rhode Island researcher. Much like ... dismissed// as the fertile imagination of a maverick researcher, which ... control programmes. And while you weigh the pros and cons ... story of why the most famous ‘don’t’ of almost all ...
... Fresh statistics show a phenomenal rise in sexually transmitted ... of the most common treatable sexually transmitted diseases affecting ... in its incidence rates across the Australian subcontinent. with ... younger age groups with no gender distinction among the ...
... Haryana: This one's a very different kind of war for ... some. You bomb bacteria, not civilian populations//. And the retired ... the past 13 years. ,What began in 1993 ... and Leprosy Eradication (ABLE). Made possible through generous NRI funding ...
... Diligent study has helped telemedicine researchers at University of Queensland ... virtually shrinking ominous distances between cities and remote settlements in ... Eliza was created by the Centre for Online Health one ... Which is affiliated to the University of Queensland, Eliza ...
Cached Medicine News:Health News:Grant Encourages Drug Testing Sans Animals 2Health News:Tilt the Scales in Your Favor by Simply Weighing Yourself Everyday! 2Health News:Sexually Transmitted Diseases Soaring Due To Unsafe Sex 2Health News:Robots Help Bring Specialist Doctors To You In A Trice 2
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
... an effort to improve on the ... toxicology, abused drugs, and immunosuppressants tests, ... which incorporates random access capabilities. Although ... undergone several important changes in the ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Medicine Products: